Valuation: Gilead Sciences, Inc.

Market Cap 18TCr 93TCr 16TCr 15TCr 13TCr 25TCr 17,41400Cr 25TCr 1,77400Cr 68TCr 8,83000Cr 68TCr 67TCr 28,16000Cr P/E 2026 *
-44.3x
P/E 2027 * 18.2x
Enterprise Value 20TCr 1,02000Cr 17TCr 16TCr 15TCr 28TCr 19,02100Cr 28TCr 1,93800Cr 75TCr 9,64400Cr 74TCr 73TCr 30,75800Cr EV / Sales 2026 *
6.46x
EV / Sales 2027 * 5.83x
Free-Float
99.88%
Yield 2026 *
2.25%
Yield 2027 * 2.29%
1 day+2.65%
1 week+1.08%
Current month-0.85%
1 month+2.87%
3 months+19.38%
6 months-1.12%
Current year+9.28%
1 week 61
Extreme 61
62.65
1 month 59.88
Extreme 59.88
64.44
Current year 52.08
Extreme 52.079999
66.06
1 year 48.98
Extreme 48.975
66.06
3 years 27.26
Extreme 27.261666
66.06
5 years 22.04
Extreme 22.039999
66.06
10 years 17.05
Extreme 17.048333
66.06
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.65%+1.08% - - 18TCr
-0.04%+1.44%+52.38%+98.04% 1,01500Cr
-0.19%-1.21%+49.87%+64.68% 64TCr
+0.20%+5.49%+20.61%+72.53% 46TCr
-0.22%+2.88%+38.48%+37.98% 35TCr
-0.07%+1.82%+16.57%+23.39% 26TCr
-0.31%+2.02%+6.15%+10.75% 25TCr
-0.91%-3.77%+37.88%+45.12% 21TCr
-1.60%-5.51%-22.30%-58.60% 19TCr
+0.26%-0.45%+29.71%+92.91% 18TCr
Average -0.11%-3.35%+25.48%+42.98% 39.67TCr
Weighted average by Cap. -0.12%-2.21%+34.49%+59.33%

Financials

2026 *2027 *
Net sales 3.07TCr 16TCr 2.66TCr 2.51TCr 2.28TCr 4.27TCr 2,94500Cr 4.31TCr 30TCr 12TCr 1,49300Cr 12TCr 11TCr 4,76200Cr 3.27TCr 17TCr 2.83TCr 2.68TCr 2.42TCr 4.55TCr 3,13500Cr 4.58TCr 32TCr 12TCr 1,59000Cr 12TCr 12TCr 5,07000Cr
Net income -427.47Cr -2.2TCr -370.28Cr -350.13Cr -316.99Cr -594.92Cr -41TCr -599.4Cr -4.18TCr -1.61TCr -21TCr -1.61TCr -1.57TCr -66TCr 1.03TCr 5.29TCr 890.02Cr 841.61Cr 761.93Cr 1.43TCr 99TCr 1.44TCr 10TCr 3.86TCr 50TCr 3.86TCr 3.77TCr 1,59400Cr
Net Debt 1.67TCr 8.62TCr 1.45TCr 1.37TCr 1.24TCr 2.33TCr 1,60600Cr 2.35TCr 16TCr 6.3TCr 81TCr 6.29TCr 6.15TCr 2,59700Cr 912.45Cr 4.7TCr 790.37Cr 747.37Cr 676.62Cr 1.27TCr 88TCr 1.28TCr 8.92TCr 3.43TCr 44TCr 3.43TCr 3.35TCr 1,41500Cr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
15/26/15 R$62.65 +2.65% 61
11/26/11 R$61.27 +0.44% 30
10/26/10 R$61.00 -1.58% 314
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
146.41USD
Average target price
158.15USD
Spread / Average Target
+8.02%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!